Navigation Links
Researchers explore the antidepressant effects of ketamine
Date:2/21/2008

Philadelphia, PA, February 21, 2008 Drug treatments for depression can take many weeks for the beneficial effects to emerge. The excruciating and disabling nature of depression highlights the urgency of developing treatments that act more rapidly. Ketamine, a drug used in general medicine as an anesthetic, has recently been shown to produce improvements in depressed patients within hours of administration. A new study being published in the February 15th issue of Biological Psychiatry provides some new insight into the mechanisms by which ketamine exerts its effects.

Ketamine is classified as an N-methyl d-aspartate (NMDA) glutamate receptor antagonist. Maeng and colleagues now provide new evidence that these antidepressant effects of NMDA receptor antagonists are mediated by their ability to increase the stimulation of -amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) glutamate receptors. In other words, their findings indicate that the antidepressant-like effects of drugs like ketamine are dependent on AMPA receptor stimulation. This suggests that drugs that enhance AMPA receptor function might have rapid antidepressant properties.

Dr. Husseini Manji, corresponding author on this paper and a Deputy Editor of Biological Psychiatry, explains that by aiming new medications at more direct molecular targets, such as NMDA or AMPA, we may be able to bypass some of the steps through which current antidepressants indirectly exert their effects a roundabout route that accounts for the long time it takes for patients to begin feeling better with the conventional medications. He adds, Todays antidepressant medications eventually end up doing the same thing, but they go about it the long way around, with a lot of biochemical steps that take time. Now weve shown what the key targets are and that we can get at them rapidly.

This study is especially important because even though this important antidepressant effect has been found in ketamine, its use also has significant drawbacks. According to John H. Krystal, M.D., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, the only NMDA receptor antagonist found to be effective so far, ketamine, produces transient changes in perception and impairments in cognition. It is also in the same class of drugs as PCP (phencyclidine) and can cause hallucinations, among other side effects. Dr. Krystal notes that it is possible that drugs that directly enhance the activity of AMPA glutamate receptors, the AMPAkines, would have antidepressant effects similar to ketamine, without the unwanted side effects. Exploring the antidepressant effects of the AMPAkines will now be an important target for researchers.


'/>"/>

Contact: Jayne Dawkins
ja.dawkins@elsevier.com
215-239-3674
Elsevier
Source:Eurekalert

Related medicine news :

1. Researchers Make Stem Cells That Secrete Insulin
2. U of M researchers determine structure of protein that mutates DNA of the AIDS virus HIV-1
3. Researchers create first chikungunya animal model
4. Researchers aim to prevent global prematurity and stillbirths
5. Researchers Aim to Prevent Global Prematurity and Stillbirths
6. UH researchers study Hispanic childrens activities, views on places to play
7. Researchers discover new way to reverse poor circulation and heal wounds
8. Bacterial toxin closes gate on immune response, Penn researchers discover
9. UD researchers discover technique for repairing gene defect that causes spinal muscular atrophy
10. Veterinary researchers study poultry virus as human cancer treatment
11. UD researchers discover promising technique for repairing gene that causes spinal muscular atrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... practitioner, is known locally for a series of therapeutic sessions to help Los ... their characters and in their lives. The series, known as “Mindfulness for Actors ...
(Date:2/10/2016)... ... February 10, 2016 , ... MetLoop ... revolutionary new 2.0 version at the International Roofing Expo in Orlando, Florida on ... the world's most advanced weather technology in the hands of consumers, roofing contractors, ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Wickman Agency in Garland, ... the local community. Pledging to select a new beneficiary every 60 days, the ... Their goal is to bring community awareness to important local causes by forming ...
(Date:2/10/2016)... ... 2016 , ... Ongoing news of the ravages of traumatic brain injury (TBI) ... survey that takes a closer look at cases of TBI being managed by their ... TBI among the aging population, and identifies the challenges associated with their care. , ...
(Date:2/10/2016)... ... 10, 2016 , ... Armune BioScience signed a definitive agreement with ... service centers across the country. Launched in April of 2015, Apifiny is the only ... cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 10, 2016  Visage Imaging ... Medicus Ltd. (ASX: PME), has announced that the American ... Florida (UF) have selected the Visage 7 Enterprise ... of the Emergent/Critical Care Imaging SIMulation (SIM). SIM ... Diagnostic Imaging Program (WIDI), a multi-faceted and fully-integrated ...
(Date:2/10/2016)... , February 10, 2016 CERS ), ... ADMS ) and Celldex Therapeutics, Inc. (NASDAQ: CLDX ... MDVN ), Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS ) and ... Today,s latest Orphan Drug Designations become vitally important in the ... to novel drugs and biologics which are defined as those ...
(Date:2/10/2016)... Israel , February 10, 2016 /PRNewswire/ ... leader in the field of cartilage repair, announces the ... 5, 2016. The $15 million investment was led by ... pharmaceutical manufacturer, and was joined by existing Regentis investors ... and both the Technion Research & Development Foundation and ...
Breaking Medicine Technology: